Stryker

Q3 2026
Speakers

Oct 29, 2026 · 61 min

PREPARED REMARKS · INFERREDKeys: / search · Space play · ←→ ±10s · [] sections

Prepared remarks

Speaker 0

Unverified voice label

Welcome to the third quarter 2026 Stryker Earnings Call. My name is Layla, and I'll be your conference operator for today's call. ?At this time, all participants are in a listen-only mode. Following the conference, we will conduct a question and answer session. This conference call is being recorded for replay purposes. Before we begin, I would like to remind you that the discussions during this conference call will include forward-looking statements.

Factors that could cause actual results
to differ materially are discussed in the company's most recent filings with the SEC. Also, the discussions will include certain non GAAP financial measures. Reconciliations to the most directly comparable GAAP financial measures can be found in today's press release ?that is an exhibit to Stryker's current report on Form 8K filed today with the SEC. ?I will now turn the call over to Mr.

Kevin Lobo, Chair and Chief Executive Officer. You may proceed,

Passages & reports (8)
  • Welcome to the third quarter 2026 Stryker Earnings Call. My name is Layla, and I'll be you…
  • At
  • this time, all participants are in a listen-only mode. Following the conference, we will c…
  • to differ materially are discussed in the company's most recent filings with the SEC. Also…
  • that
  • is an exhibit to Stryker's current report on Form 8K filed today with the SEC.
  • I
  • will now turn the call over to Mr. Kevin Lobo, Chair and Chief Executive Officer. You may …

Speaker unclear

?sir.

Passages & reports (1)
  • sir.

Speaker 1

Unverified voice label

Welcome to Stryker's third quarter earnings call. Joining me today are Preston Wells, CFO, ?and Nick Mead, Vice President of Investor Relations. Before I begin, I'd like to congratulate Spencer Stiles on his appointment ?as Stryker's next CEO. Spencer has spent nearly three decades at Stryker helping shape our strategy, strengthen our culture, and drive our growth. You will have additional opportunities to hear more from him at various investor events over the next few months, and I am confident you will come away with an even greater appreciation of his capabilities to lead Stryker into the future. ?

For
today's call, I'll provide an overview of our performance. Nick will then provide a brief MA update, followed by Preston with additional details on financial results and guidance. We will then open the call to QA. Turning to our third quarter performance, organic sales growth for the quarter was 7.7%, with 9.1% growth in med surge and neurotechnology, and 5.9% growth in orthopedics. ?Our endoscopy and orthotec divisions delivered double-digit performances, and medical also delivered near double-digit growth.

While we delivered solid growth in several businesses, our overall results fell short of our expectations. As Preston mentioned during an investor conference this September, we are facing challenges with our hip and knee
and peripheral vascular businesses. Beginning with hips and knees, it is now clear that there is a market slowdown. ?In the US, we are seeing slower procedural growth amid affordability concerns from higher insurance premiums and deductibles.

We are also observing increased preauthorization denials, creating additional friction and delaying patient access to treatment. Europe and the Middle East have also remained soft amid regional disruption,
strike-related delays, and government funding decisions. ?In addition to the softer market, we have not been winning at our historical rate. 2026 has been an unusual year, marked by the cyber incident in the first quarter and an SAP implementation within our orthopedic businesses in July.

This is the last of our businesses to go on to SAP. And
while the system is functioning well, it has created a distraction for our teams and delayed our visibility of market conditions. Although Mako sales have been strong again this year, we are behind our expectations on new product sales from Mako RPS and Triathlon Gold. ?The feedback on these innovations is very positive, ?but the cyber incident and SAP implementation have impacted our commercial execution.

We are taking actions to improve competitive conversions and new product adoption. Finally, as a leader in Power Tools, we are excited about bringing a powered hip impaction solution to the market next year, addressing an important product
gap ?in our HIPAA portfolio. We remain confident in the long term attractiveness of the large joint reconstruction market, supported by favorable demographics and expanded access through new sites of care, such as ASCs.

Next, I'd like to give an update on our vascular business, which reflects a sequential improvement from
last quarter. ?The third quarter included one time revenue from our peripheral vascular joint venture in China as a result of achieving a regulatory approval milestone in September. This benefit helped offset the impact of lost revenue from the ongoing supply disruption that we discussed during our last earnings call.

Our teams made meaningful progress
restoring supply throughout the quarter, and we now expect inventory levels and product availability to continue normalizing through the end of the ?year. While this has been a challenging period, we remain convicted in the outlook for peripheral vascular as a growth business accretive to Stryker. Looking ahead to 2027, we expect to begin commercializing AVS's IVL platform and also look forward to important data from our Peerless II study, ?a flowetriever. ?

We
are excited about our recently announced strategic investment in CMR surgical, which Nick will cover in his section. Our updated organic sales guidance anticipates a similar overall organic growth rate for the company in Q4 as we achieved in Q3. This assumes a continuation of the procedure environment we observed this quarter, as well as continued strong capital demand, where we continue to maintain an elevated order book.

Meanwhile, our successful efforts on margin expansion are limiting the impact of our sales shortfall on adjusted EPS, and we continue to generate strong
cash flows. As this is the last of 57 earnings calls as CEO, I would have preferred to deliver better news. But we've demonstrated before that our business is resilient, our foundation and culture are strong, and we remain confident in our ability to deliver on our long-range financial commitments. ?

I
will now turn the call over to Nick.

Passages & reports (39)
  • Welcome to Stryker's third quarter earnings call. Joining me today are Preston Wells, CFO,
  • and
  • Nick Mead, Vice President of Investor Relations. Before I begin, I'd like to congratulate …
  • as
  • Stryker's next CEO. Spencer has spent nearly three decades at Stryker helping shape our st…
  • of his capabilities to lead Stryker into the future.
  • For
  • today's call, I'll provide an overview of our performance. Nick will then provide a brief …
  • surge and neurotechnology, and 5.9% growth in orthopedics.
  • Our
  • endoscopy and orthotec divisions delivered double-digit performances, and medical also del…
  • and peripheral vascular businesses. Beginning with hips and knees, it is now clear that th…
  • In
  • the US, we are seeing slower procedural growth amid affordability concerns from higher ins…
  • strike-related delays, and government funding decisions.
  • In
  • addition to the softer market, we have not been winning at our historical rate. 2026 has b…
  • while the system is functioning well, it has created a distraction for our teams and delay…
  • The
  • feedback on these innovations is very positive,
  • but
  • the cyber incident and SAP implementation have impacted our commercial execution. We are t…
  • gap
  • in
  • our HIPAA portfolio. We remain confident in the long term attractiveness of the large join…
  • last quarter.
  • The
  • third quarter included one time revenue from our peripheral vascular joint venture in Chin…
  • restoring supply throughout the quarter, and we now expect inventory levels and product av…
  • year.
  • While this has been a challenging period, we remain convicted in the outlook for periphera…
  • a
  • flowetriever.
  • We
  • are excited about our recently announced strategic investment in CMR surgical, which Nick …
  • we observed this quarter, as well as continued strong capital demand, where we continue to…
  • cash flows. As this is the last of 57 earnings calls as CEO, I would have preferred to del…
  • I
  • will now turn the call over to Nick.

Speaker unclear

?Thank

Passages & reports (1)
  • Thank

Speaker 2

Unverified voice label

you, Kevin. My comments today will focus on MA and will highlight two recent transactions. As announced earlier this week, we have completed our acquisition of ZuriMed, which expands the support we can provide to specialists across sports medicine and arthroplasty. ZuriMed's differentiated fiber locker technology is designed to increase biomechanical strength and rotator cuff repair and provides a broader platform for orthopedic soft tissue augmentation.

Next, we recently announced an investment in CMR surgical and agreement to act as the exclusive U.S. sales agent
?for the Virces platform. Soft tissue robotics is an attractive adjacency that is a natural extension of striker's strengths in endoscopy, visualization, and enabling technologies. Versius has been used in more than 50,000 procedures globally, ?and its scalable design can support broader adoption of robotic assisted surgery. ?

With
its new Virseus Plus system, approved indications, technology, and growing global clinical experience, we believe now is the right time to partner with CMR and begin scaling the U.S. market through a thoughtful, disciplined approach. Together, these transactions reflect our continued focus on investing in opportunities that support durable long-term growth and value creation. I'll now turn the call over to Preston to further discuss our third quarter financial performance.

Passages & reports (9)
  • you, Kevin. My comments today will focus on MA and will highlight two recent transactions.…
  • to increase biomechanical strength and rotator cuff repair and provides a broader platform…
  • for
  • the Virces platform. Soft tissue robotics is an attractive adjacency that is a natural ext…
  • and
  • its scalable design can support broader adoption of robotic assisted surgery.
  • With
  • its new Virseus Plus system, approved indications, technology, and growing global clinical…
  • investing in opportunities that support durable long-term growth and value creation. I'll …

Speaker 1

Thanks, Nick.

Passages & reports (1)
  • Thanks, Nick.

Speaker 3

Unverified voice label

Detailed financial information is included in today's press release. I'll focus on our third quarter financial performance, the key drivers of our results, and our updated outlook for the remainder of the year. Organic sales grew 7.7% in the quarter against strong prior year comparable. Pricing contributed 0.1% to growth, while foreign currency had no impact on sales. ?The quarter had the same number of selling days as the prior year quarter.

Adjusted earnings per share were $3.52, up 10.3% from the same quarter last year, driven by gross margin expansion supported by operational efficiencies, along with disciplined expense management. Turning to segment performance, med surge and
neurotechnology organic sales grew 9.1%, with growth of 9.6% in the US and 7.2% internationally. Instruments US organic sales grew 4.8% against a strong 15.3% prior year comparable, ?with double digit growth in our interventional spine and surgical technologies businesses.

This performance was offset by softer performance in our neurosurgical business due to the deferral of capital purchases ahead of the upcoming launch of our Sonopet 3 ultrasonic aspiration platform, which received FDA 510K clearance earlier this
month. Endoscopy US organic sales grew 13%, supported by continued robust demand for operating room infrastructure and renovations, and strong performance in sports medicine, where double-digit growth continues to be driven by its expanded range of shoulder implant products.

Medical U.S. organic sales increased 10%,
including double-digit performances for stage and smart care businesses, while capital demand remains elevated across our portfolio. Vascular U.S. organic sales grew 13%, primarily reflecting the drivers that Kevin discussed earlier. Internationally, MedSurge and Neurotechnology organic sales growth of 7.2% included broad strength across endoscopy, medical, and instruments. Geographically, growth was led by robust performances in Australia, Germany, Canada, and India.

Orthopedics organic sales grew 5.9%, with growth of 6.4% in the US and 4.4%
internationally. US knees organic sales grew 1.3%, while US HIPS organic sales declined 0.6% against strong prior year comparables. ?As Kevin noted, we remain focused on strengthening our commercial execution behind our enabling technology platforms and new products to restore momentum and drive share gains. US trauma and extremities organic sales grew 4.5% against a strong 13.2% prior year comparable.

Current year growth reflected continued
strong performance in upper extremities, supported by continued momentum across our differentiated portfolio, including early success of Mako shoulder on Mako 4. We are expecting strong growth for trauma and extremities in the fourth quarter. US orthotech organic sales increased 18%, supported by continued strength in Mako sales and robust demand for orthopedic power tools. Internationally, orthopedics organic sales grew 4.4%, supported by knees, orthotech, and trauma and extremities, and was led regionally by Canada, Japan, Australia, Germany, and India.

Turning to margins and other income statement
items, adjusted gross margin was 65.4%, up 40 basis points from the third quarter of 2025. ?The improvement reflected a net tariff benefit and benefits from operational efficiencies. Adjusted operating margin was 26.2% of sales, up 60 basis points from the third quarter of 2025, reflecting the gross margin improvement and continued expense discipline. Adjusted other income and expense was $91 million, down $25 million from the same quarter last year, reflecting lower debt levels.

We now expect adjusted other income and expense to be approximately $400 million for the full year.
?The third quarter had an adjusted effective tax rate of 16%, and we now expect our full year effective tax rate to be in the range of 15.5% to 16%. Turning to cash and capital allocation, we ended the third quarter with approximately $3.3 billion of cash and cash equivalents and year to date cash from operations of $3.3 billion, an increase of approximately 14% compared to the prior year.

During the quarter, we repurchased $1 billion of shares under our previously existing share repurchase program. Additionally,
?we received board authorization for another $3 billion towards future share repurchases, which provides us additional flexibility while preserving our capacity to invest in strategic MA growth opportunities. Based on our year to date results, we are revising our full year guidance to reflect softer hip and knee procedure trends, lingering supply constraints in peripheral vascular, and mitigation of operational execution risk related to capital equipment sales.

We now expect full year organic net sales growth of 6.5% to 7%, and adjusted net earnings per share of $14.80 to $14.90. Our revised adjusted earnings per share
outlook reflects continued expense discipline and gross margin expansion. Looking ahead, we remain confident in the long term trajectory of our business. Our diversified portfolio, leading positions in attractive markets, robust innovation pipeline, and expanding Mako ecosystem provide a strong foundation for sustainable growth.

As we plan for 2027, our priorities remain focused on category leadership, advancing innovation, and driving operational excellence to deliver market leading sales growth while continuing to expand margins and grow earnings. We are continuing to assess market conditions, procedural volume trends, and a broader
macroeconomic environment as we finalize forecasts for 2027. While we will not provide formal guidance until early next year, we do expect to deliver growth at the high end of our markets.

With that, I will now open the call for QA.

Passages & reports (28)
  • Detailed financial information is included in today's press release. I'll focus on our thi…
  • while foreign currency had no impact on sales.
  • The
  • quarter had the same number of selling days as the prior year quarter. Adjusted earnings p…
  • neurotechnology organic sales grew 9.1%, with growth of 9.6% in the US and 7.2% internatio…
  • with
  • double digit growth in our interventional spine and surgical technologies businesses. This…
  • month. Endoscopy US organic sales grew 13%, supported by continued robust demand for opera…
  • including double-digit performances for stage and smart care businesses, while capital dem…
  • included broad strength across endoscopy, medical, and instruments. Geographically, growth…
  • internationally. US knees organic sales grew 1.3%, while US HIPS organic sales declined 0.…
  • As
  • Kevin noted, we remain focused on strengthening our commercial execution behind our enabli…
  • strong performance in upper extremities, supported by continued momentum across our differ…
  • Mako sales and robust demand for orthopedic power tools. Internationally, orthopedics orga…
  • items, adjusted gross margin was 65.4%, up 40 basis points from the third quarter of 2025.
  • The
  • improvement reflected a net tariff benefit and benefits from operational efficiencies. Adj…
  • $25 million from the same quarter last year, reflecting lower debt levels. We now expect a…
  • The
  • third quarter had an adjusted effective tax rate of 16%, and we now expect our full year e…
  • operations of $3.3 billion, an increase of approximately 14% compared to the prior year. D…
  • we
  • received board authorization for another $3 billion towards future share repurchases, whic…
  • peripheral vascular, and mitigation of operational execution risk related to capital equip…
  • outlook reflects continued expense discipline and gross margin expansion. Looking ahead, w…
  • growth. As we plan for 2027, our priorities remain focused on category leadership, advanci…
  • macroeconomic environment as we finalize forecasts for 2027. While we will not provide for…

Speaker unclear

?At

Passages & reports (1)
  • At

Speaker 0

this time we will open the floor for questions. If you would like to ask a question, please press star five on your telephone keypad. You may remove yourself at any time by pressing star five again. ?We would like to remind callers to please limit themselves to one question and one follow-up question so we can accommodate as many participants as possible. And we'll pause just a

Passages & reports (3)
  • this time we will open the floor for questions. If you would like to ask a question, pleas…
  • We
  • would like to remind callers to please limit themselves to one question and one follow-up …

Questions & answers

Speaker unclear

?moment.

Passages & reports (1)
  • moment.

Speaker unclear

?Okay,

Passages & reports (1)
  • Okay,

Speaker 0

our first question will come from Robbie Marcus with JP Morgan. Your line is now unmuted. Please go ahead.

Passages & reports (1)
  • our first question will come from Robbie Marcus with JP Morgan. Your line is now unmuted. …

Speaker 4

Unverified voice label

Great. Good afternoon. Thank you for taking the questions. Two for me. First, Kevin, clearly disappointing to hear about the Ortho market. Where do you think market growth is now? Anything the industry could do to help stend the decline? Is it extremities as well as hips and knees? And uh then I have a follow-up. Thanks.

Passages & reports (2)
  • Great. Good afternoon. Thank you for taking the questions. Two for me. First, Kevin, clear…
  • as well as hips and knees? And uh then I have a follow-up. Thanks.

Speaker unclear

?Uh thanks,

Passages & reports (1)
  • Uh thanks,

Speaker 2

Robbie.

Passages & reports (1)
  • Robbie.

Speaker unclear

?Uh

Passages & reports (1)
  • Uh

Speaker 1

what we saw was really a slowdown in the hip and knee portion of the market, not really extremities. Our extremities business, especially upper extremities, continues to ?be very high growth. So we're not seeing much of an impact there. It's really the hip and knee market where we're seeing the slowdown. Uh it's hard to estimate exactly, but I would say market growth is kind of in the two and a half uh percent range this year.

That's what we think, which
is definitely a step down from where it has been the last five, six years. And as you know, it took us a while to figure this out. Uh, there's a lot of noise with our cyber event, noise with some of the things going on competitively, and then our SAP implementation, which really delayed a lot of order entry.

So we really started to figure this out kind of in early September when Preston made his remarks at the investor conference. But uh this has happened before in my tenure, earlier in my tenure, where we've had kind of a year like this and things have turned. So we'll
we'll have to monitor this closely. It certainly was a surprise for ?us, and and that is reflected in our kinds.

Passages & reports (8)
  • what we saw was really a slowdown in the hip and knee portion of the market, not really ex…
  • be
  • very high growth. So we're not seeing much of an impact there. It's really the hip and kne…
  • is definitely a step down from where it has been the last five, six years. And as you know…
  • a lot of order entry. So we really started to figure this out kind of in early September w…
  • we'll have to monitor this closely. It certainly was a surprise for
  • us,
  • and and that is reflected in our kinds.

Speaker 4

I I appreciate you're not guiding for 2027 at this point. There's a lot of moving pieces here as we think about some of the shipping market dynamics. Where do you think striker's weighted average and market growth is as we uh head into year end? And um, ?you know any takes we should be considering um respective down the margins. I know this is a pretty healthy margin business in order to how we should think about that down the PL.

Thanks.

Passages & reports (3)
  • I I appreciate you're not guiding for 2027 at this point. There's a lot of moving pieces h…
  • you
  • know any takes we should be considering um respective down the margins. I know this is a p…

Speaker 3

Yeah. Robbie, so so in terms of the the weighted acromarket growth, I mean we said a year ago at our investor conference that that uh we believe we were about 6% is what we thought we were. Now, obviously, if you take into account what's happening uh across the joint replacement, the hip and knee market, ?you know, that's probably taken a little bit of a tick down from there.

So we'll we'll we're continuing to look at and understand kind of where that where that nets out. So I think if we have those couple of pieces, you can see we're probably a little bit of a step down from where
we were we said a year ago in terms of our overall growth rate. And as I mentioned in my remarks, our goal will be as we we start on 2027, is that we will perform at the high end of those markets as we we go into there.

Looking at the margins, you know,
our expectation around margins is that you know we we want to continue to deliver what we committed to uh a year ago as well. ?You know, we feel like we're putting the right the right plans in place from an operational excellence standpoint. We're really getting after our manufacturing element and gross margins uh from that standpoint, as well as just looking at other efficiencies up and down the PL.

So you're right, the joint replacement market is certainly a
more profitable gross margin business, but overall we feel like we're putting the right pieces in place to continue to try to drive our margin improvement year over

Passages & reports (9)
  • Yeah. Robbie, so so in terms of the the weighted acromarket growth, I mean we said a year …
  • knee market,
  • you
  • know, that's probably taken a little bit of a tick down from there. So we'll we'll we're c…
  • we were we said a year ago in terms of our overall growth rate. And as I mentioned in my r…
  • our expectation around margins is that you know we we want to continue to deliver what we …
  • You
  • know, we feel like we're putting the right the right plans in place from an operational ex…
  • more profitable gross margin business, but overall we feel like we're putting the right pi…

Speaker unclear

?year.

Passages & reports (1)
  • year.

Speaker unclear

?Our

Passages & reports (1)
  • Our

Speaker 0

next question will come from Larry Beagleson with Wells Fargo. Your line is open. Please go ahead.

Passages & reports (1)
  • next question will come from Larry Beagleson with Wells Fargo. Your line is open. Please g…

Speaker 5

Unverified voice label

Thanks for taking the question. So Kevin, uh given this is your last earnings call, uh congratulations on on creating a a lot of shareholder value uh at Stryker and Spencer, uh congratulations on your new role. Um I wanted to start with the uh the CMR investment, actually. Um, wh why is CMR the right partner for you? You know, how will you and CMR compete against uh the bank incumbent?

And if you do decide to acquire it, you know, how will you absorb
?you know the high cost of developing and marketing a competitive soft tissue robot? And then have one follow-up.

Passages & reports (4)
  • Thanks for taking the question. So Kevin, uh given this is your last earnings call, uh con…
  • the right partner for you? You know, how will you and CMR compete against uh the bank incu…
  • you
  • know the high cost of developing and marketing a competitive soft tissue robot? And then h…

Speaker unclear

?Yeah,

Passages & reports (1)
  • Yeah,

Speaker 6

Unverified voice label

thanks, Larry.

Passages & reports (1)
  • thanks, Larry.

Speaker unclear

?Look, the the

Passages & reports (1)
  • Look, the the

Speaker 1

soft tissue robotic market is very appealing. As you know, I've been talking about it for years. We've looked at every robot around the world um and had multiple looks at these robots. When Verseus Plus came along, the upgraded version of Verseus, we we got a chance to see something that we felt very excited about. We feel it is the is the best robot on the market to be able ?to succeed in multiple sites of care.

The modular nature makes it great for the ambulatory surgery center as well as working well in hospitals. And frankly, robotic penetration is very low in general surgery. So we look at winning as being able to convert open surgery and convert laparoscopic surgery to robotic, regardless
of competing with the incumbent. There's plenty of room for two players in the market. But this will work in hospitals.

This will work very well for high volume procedures like colcystectomies and appendectomies and hernias. And so it can be a very high volume, simple to use, small platform
robot that's highly, highly functional. And ?to your question about risk, one of the reasons we're going about it in this manner is we want to de-risk this and have our people do the commercialization in the US as an investor, but not a full owner.

Our hope and our plan is that we will eventually purchase this. We're not going to
get into details about when that would be, but uh, but that is our plan. This is our bet ?in the soft tissue robotic place. We're putting a lot of resources on this. And uh that is our expectation that we will be able to take out the asset and be able to drive value for Stryker.

We've done this before with Mako, and we had the challenges of developing that. This is further along, frankly,
in its journey than Mako was when we acquired Mako. And again, we're very excited. It's a very high growth segment of MedTech. And we believe this is going to be a winning solution that we are hopeful to acquire in the not too distant

Passages & reports (12)
  • soft tissue robotic market is very appealing. As you know, I've been talking about it for …
  • excited about. We feel it is the is the best robot on the market to be able
  • to
  • succeed in multiple sites of care. The modular nature makes it great for the ambulatory su…
  • of competing with the incumbent. There's plenty of room for two players in the market. But…
  • robot that's highly, highly functional. And
  • to
  • your question about risk, one of the reasons we're going about it in this manner is we wan…
  • get into details about when that would be, but uh, but that is our plan. This is our bet
  • in the
  • soft tissue robotic place. We're putting a lot of resources on this. And uh that is our ex…
  • in its journey than Mako was when we acquired Mako. And again, we're very excited. It's a …

Speaker unclear

?future.

Passages & reports (1)
  • future.

Speaker 5

That's helpful. And um, Kevin, um, it's been a while since the last new product super cycle. You talked about the recent sonopec clearance, ?you have the hip impactor next year and the peered list two data. What other products or growth drivers would you highlight for next year? Thank

Passages & reports (3)
  • That's helpful. And um, Kevin, um, it's been a while since the last new product super cycl…
  • you
  • have the hip impactor next year and the peered list two data. What other products or growt…

Speaker unclear

?you.

Passages & reports (1)
  • you.

Speaker 1

Well, we have the next version of Neptune, which is our big waste management platform within uh within instruments that's coming in the first half of next year. That's going to be a very exciting launch. ?We have the ABS product, as you know, that uh we're expecting FDA approval towards the end of this year. That'll be a shot in the arm for our uh peripheral vascular business.

And um, and we have in the not too distant future, we're not going to give you dates. We have System 10 coming
for power tools, we have 1888 coming uh as well for endoscopy. And so we're going to continue to be launching products on a on a pretty sustained basis across. And I'm not even getting into all the smaller products that we have.

Obviously, we've acquired a great platform for sports medicine with ZuriMed that'll
plug right into our existing shoulder businesses. And so there are a bunch of other products, which we'll get into later on earning other calls, but major platforms, Neptune major platform, Sonopet major platform, 1888 coming, System 10 coming. ?So we have a lot. And don't forget, you know, Mako RPS is just getting started, ?uh, Triathon Gold just getting started.

That they medial stabilized insert is doing very
?well. And so uh the ?the powered impactor is very important in hips for us. That is a really important gap. To be able to do competitive conversions, having that powered impactor is going to be very important for us in the hip business.

Passages & reports (13)
  • Well, we have the next version of Neptune, which is our big waste management platform with…
  • We
  • have the ABS product, as you know, that uh we're expecting FDA approval towards the end of…
  • for power tools, we have 1888 coming uh as well for endoscopy. And so we're going to conti…
  • plug right into our existing shoulder businesses. And so there are a bunch of other produc…
  • So
  • we have a lot. And don't forget, you know, Mako RPS is just getting started,
  • uh,
  • Triathon Gold just getting started. That they medial stabilized insert is doing very
  • well.
  • And so uh the
  • the
  • powered impactor is very important in hips for us. That is a really important gap. To be a…

Speaker unclear

?Our

Passages & reports (1)
  • Our

Speaker 0

next question will come from Joanne Wunsch with City.

Passages & reports (1)
  • next question will come from Joanne Wunsch with City.

Speaker 6

Thank you, good afternoon, And congratulations to you both. I do have a memory of ebbs and flows in the orthopedics market and we had the new market. But generally, could you remind what brought us out the last time and what can be learned

Passages & reports (1)
  • Thank you, good afternoon, And congratulations to you both. I do have a memory of ebbs and…

Speaker 0

from that to think about bringing us out this

Passages & reports (1)
  • from that to think about bringing us out this

Speaker unclear

?time?

Passages & reports (1)
  • time?

Speaker 1

Well, in the past, sometimes it's been tied to economic activity. So when you see it in the economic pressures, people feeling strained financially. I mean, there are patients that today are having trouble being able to make their deductible because their deductibles are higher and to be able to fund their deductible, they're actually living with pain a little bit longer than they would like to.

So as sort of economic conditions tend to improve for the, let's call an average person in
?the in the in the in the market, then you start to see the demand pick up. And frankly, these diseases are degenerative. So you can delay these for a while, but the pain reaches the point where you can't sleep at night. And so we see this as not a market that's going to go away.

It's just there's this temporary delay that's happening right now, and the market will come back. It's hard to predict exactly when, but it has historically tied more to sort of economic cycles, if you go back, uh Joanne. I think that's a correlation you'll you'll probably notify.

Passages & reports (5)
  • Well, in the past, sometimes it's been tied to economic activity. So when you see it in th…
  • living with pain a little bit longer than they would like to. So as sort of economic condi…
  • the
  • in the in the in the market, then you start to see the demand pick up. And frankly, these …
  • away. It's just there's this temporary delay that's happening right now, and the market wi…

Speaker 6

Helpful, thank you. And I think just to pick up from a previous

Passages & reports (1)
  • Helpful, thank you. And I think just to pick up from a previous

Speaker 0

um uh question, ?to say you grow at the high end of where your market growth is, we're all gonna be updating our models and talking about lots of fun stuff. Can you give us some parameters

Passages & reports (3)
  • um uh question,
  • to
  • say you grow at the high end of where your market growth is, we're all gonna be updating o…

Speaker 6

around that?

Passages & reports (1)
  • around that?

Speaker 0

Um, just give us some footing for as we think about next year. ?Thank you.

Passages & reports (3)
  • Um, just give us some footing for as we think about next year.
  • Thank
  • you.

Speaker 3

Yeah, Joanne, I ?would I would just point you back to to what we said a year ago again, in terms of what we think our Whamger is across all of our businesses. I mean, we're not gonna obviously go detailed business by business, but if we look at just that overall Wamger, then ?you know think about this new kind of reality that we're living within the the HIPAA market, and that probably takes a little bit of a tick down.

And then again, our expectation is that we're gonna we're gonna grow faster than what that looks

Passages & reports (5)
  • Yeah, Joanne, I
  • would
  • I would just point you back to to what we said a year ago again, in terms of what we think…
  • you
  • know think about this new kind of reality that we're living within the the HIPAA market, a…

Speaker unclear

?like

Passages & reports (1)
  • like

Speaker unclear

?your

Passages & reports (1)
  • your

Speaker 0

next question will come from Ryan Zimmerman with US Bank Corp BTIG your line is unmuted please go

Passages & reports (1)
  • next question will come from Ryan Zimmerman with US Bank Corp BTIG your line is unmuted pl…

Speaker unclear

?ahead and uh

Passages & reports (1)
  • ahead and uh

Speaker 5

good afternoon

Passages & reports (1)
  • good afternoon

Speaker unclear

?and Kevin uh 57 quarters is uh is the nice road and congratulations um on uh the fourth quarter I think if you look at

Passages & reports (1)
  • and Kevin uh 57 quarters is uh is the nice road and congratulations um on uh the fourth qu…

Speaker 4

the implied math you know it shakes out to around seven point nine percent organic you know roughly in line with kind of what you guys saw this quarter. Preston you know you you did highlight the areas that you think are going to be weak, orthopedics, peripheral vascular, et cetera. Maybe help us think about kind of what's accretive in the implied organic growth for fourth quarter, where you're seeing momentum, where you're seeing strength.

It sounds like extremities is holding up nicely in some of the other

Passages & reports (2)
  • the implied math you know it shakes out to around seven point nine percent organic you kno…
  • about kind of what's accretive in the implied organic growth for fourth quarter, where you…

Speaker 5

med surge businesses as well, ?but just help us offset some of that weakness or where you see that ?could be offset.

Passages & reports (5)
  • med surge businesses as well,
  • but
  • just help us offset some of that weakness or where you see that
  • could
  • be offset.

Speaker 3

Absolutely. So I mean again, we we expect that that, ?like you said, I think that that implied number is pretty, pretty good. Um, you know, I think we'll we'll be looking at areas like trauma extremities, as you mentioned. We expect that to have a very strong quarter, as I mentioned in my prepared remarks. The other areas I would look at, medical will will have a really good quarter.

So we expect that to perform well. Instruments is another area that we would expect to
?have uh strong performances as well. And then I think the others, again, it's just a matter of keeping par with with some of what we've done today. As Kevin mentioned around peripheral vascular, while we still see that being pressured, it should be a little bit better underlying in terms of where we expect that to perform also.

So
?I think we have a few areas that that we'll certainly be leaning on as we we come into the fourth quarter and and we'll continue to work on on the execution in other areas that Kevin mentioned as well, even in some of those softer spaces.

Passages & reports (9)
  • Absolutely. So I mean again, we we expect that that,
  • like
  • you said, I think that that implied number is pretty, pretty good. Um, you know, I think w…
  • have a really good quarter. So we expect that to perform well. Instruments is another area…
  • have
  • uh strong performances as well. And then I think the others, again, it's just a matter of …
  • to perform also. So
  • I
  • think we have a few areas that that we'll certainly be leaning on as we we come into the f…

Speaker unclear

?And and

Passages & reports (1)
  • And and

Speaker 4

maybe turning to capital, thank you, Preston, for that and and maybe just turning to capital for a minute. I mean, you've talked about the strength of the order book, but at the same time, you know, it's kind of balanced by some of your other comments around capital. And ?and so if we could step ?back and you know give

Passages & reports (5)
  • maybe turning to capital, thank you, Preston, for that and and maybe just turning to capit…
  • and
  • so if we could step
  • back and
  • you know give

Speaker unclear

?us

Passages & reports (1)
  • us

Speaker 6

your ?view of of capital in the market maybe what you're seeing you know there's been a lot of chatter about 340

Passages & reports (3)
  • your
  • view of
  • of capital in the market maybe what you're seeing you know there's been a lot of chatter a…

Speaker unclear

?b and and the impact of hospitals and so you know would love to understand kind of where you're

Passages & reports (1)
  • b and and the impact of hospitals and so you know would love to understand kind of where y…

Speaker 6

seeing

Passages & reports (1)
  • seeing

Speaker unclear

?maybe strong capital demand uh you know at higher price points maybe versus lower price points etc but appreciate those thoughts

Passages & reports (1)
  • maybe strong capital demand uh you know at higher price points maybe versus lower price po…

Speaker 2

sure hey Ryan this this is Nick um I'll I'll take that from a capital perspective so ?you know really there's two components there there's the the demand side of the capital equation, and then there's that us executing on the demand. From a demand perspective, the order book remains strong and elevated. And of course, there's nuances by business, but by and large, the capital environment remains healthy.

What we're focused on is
continue to execute on that demand from a capacity perspective, and we're laser focused to ensure that we have plans in place to deliver on all those businesses that Preston just mentioned in terms of putting together the full year.

Passages & reports (4)
  • sure hey Ryan this this is Nick um I'll I'll take that from a capital perspective so
  • you know
  • really there's two components there there's the the demand side of the capital equation, a…
  • continue to execute on that demand from a capacity perspective, and we're laser focused to…

Speaker 0

Your next question will come from the line of Travis Steed with Bank of America. Please go ahead.

Passages & reports (1)
  • Your next question will come from the line of Travis Steed with Bank of America. Please go…

Speaker 5

Hey, thanks ?for the question. Spencer, congrats on the CEO job. When you think about calling out market slowdown versus the winning rate, and what data points are helping kind of build out what's the market slowdown versus the the win rate. And it it seems like, at least to me, from where I sit, maybe things got a little worse later in September versus kind of what was being messaged at the September conference.

So I don't
?know if if things kind of worsened over the course of September ?uh for game as

Passages & reports (8)
  • Hey, thanks
  • for the question. Spencer,
  • congrats on the CEO job. When you think about calling out market slowdown versus the winni…
  • later in September versus kind of what was being messaged at the September conference. So …
  • know
  • if if things kind of worsened over the course of September
  • uh
  • for game as

Speaker unclear

?well. Yeah,

Passages & reports (1)
  • well. Yeah,

Speaker 1

look, I wouldn't say things worsened in September. We only gained visibility to the quarter kind of ?in the September timeframe because ?there was huge delays in order entry given the change to SAP. So we only recognized it later in the quarter, but it wasn't just something that fell ?off in the month of September. And the other thing I'd say is if if you look at our sales, we don't do bulk sales within our hip and knee business.

And so when you see our numbers, that they tend to be pretty reflective of what's happening in the market because we don't have that exaggeration
of bulk sales. And it's going to be a combination. The market's definitely slow. We know we're not losing major bits of business to the competition. So that tells us that it's mostly market related. ?But we had been gaining share at a higher rate very consistently for the past five, six years.

And our teams were distracted. They clearly weren't focused as much on this. And so that's why we think the market growth definitely declined, but we weren't taking share the way we had been taking share in the
past.

Passages & reports (11)
  • look, I wouldn't say things worsened in September. We only gained visibility to the quarte…
  • in
  • the September timeframe because
  • there
  • was huge delays in order entry given the change to SAP. So we only recognized it later in …
  • off in
  • the month of September. And the other thing I'd say is if if you look at our sales, we don…
  • of bulk sales. And it's going to be a combination. The market's definitely slow. We know w…
  • But
  • we had been gaining share at a higher rate very consistently for the past five, six years.…
  • past.

Speaker unclear

?Okay,

Passages & reports (1)
  • Okay,

Speaker 5

that's helpful. And how does the the cyber impact in 26 impact 2027? Is it ?an easy comp? Is there ?an ability to catch up in 27? ?And I just want to make sure it sounds like six percent is kind of the floor for total company growth next year. I just want to make sure I heard that correctly.

Passages & reports (7)
  • that's helpful. And how does the the cyber impact in 26 impact 2027? Is it
  • an
  • easy comp? Is there
  • an
  • ability to catch up in 27?
  • And
  • I just want to make sure it sounds like six percent is kind of the floor for total company…

Speaker unclear

?Yeah,

Passages & reports (1)
  • Yeah,

Speaker 3

so let me answer your your cyber, your cyber question. So we haven't we haven't gone through yet all the all the ?the different quarterly splits, et cetera, for next year's planning process, but certainly as you look at cyber, it'll be something that we'll have to talk about. We'll anniversary it clearly in the first quarter. But then we'll also anniversary bits of the recovery throughout the year.

So we're gonna have to really talk through as
we go through each quarter, kind of the impacts as we can kind of detail them out. But the reality is for many, much of the cyber incident, that you know, that's been made back up just at different points in time. ?And I think when we look at our performance in 27 versus 26, it's really gonna be a matter of looking at kind of overall how we're performing versus the market and any market changes that are happening uh from 26 to 27.

In terms of the floor, we're not setting guidance right now. So we're
just giving a bit of an indicator as how we're starting to think about 27.

Passages & reports (7)
  • so let me answer your your cyber, your cyber question. So we haven't we haven't gone throu…
  • the
  • different quarterly splits, et cetera, for next year's planning process, but certainly as …
  • we go through each quarter, kind of the impacts as we can kind of detail them out. But the…
  • And
  • I think when we look at our performance in 27 versus 26, it's really gonna be a matter of …
  • just giving a bit of an indicator as how we're starting to think about 27.

Speaker unclear

?Yeah,

Passages & reports (1)
  • Yeah,

Speaker 1

I think the takeaway is the market slowed down in joint replacement. Uh, we've had this challenge with the SAP that we believe will be through it affected joint replacement, also affected our core trauma business pretty significantly. ?Uh, we think that'll be will be through that. And the underlying fundamentals of our business in every other area are strong. Capital demand is very strong, ?and we have a pretty good innovation cycle.

So it's the companies, despite this quarter's uh takedown on the guide,
?uh the fundamentals are still very, very strong looking ahead.

Passages & reports (7)
  • I think the takeaway is the market slowed down in joint replacement. Uh, we've had this ch…
  • Uh,
  • we think that'll be will be through that. And the underlying fundamentals of our business …
  • and
  • we have a pretty good innovation cycle. So it's the companies, despite this quarter's uh t…
  • uh
  • the fundamentals are still very, very strong looking ahead.

Speaker 0

Your next question will come from Matthew O'Brien with Piper Sandler. Your line is open, please go ahead.

Passages & reports (1)
  • Your next question will come from Matthew O'Brien with Piper Sandler. Your line is open, p…

Speaker unclear

?Um, afternoon. Thanks for taking the questions. And Kevin,

Passages & reports (1)
  • Um, afternoon. Thanks for taking the questions. And Kevin,

Speaker 7

Unverified voice label

it's been an absolute pleasure watching me grow this business. Um ?I guess I'm still a little hung up on this hippine um commentary about Q3 here, because if I ?if I look at your orthotech number, that was really good. It still seems like generally speaking, the macro environment's really healthy. ?Um, I actually talked to CDMO yesterday, they said things are pretty steady. ?

So
I'm trying to reconcile this slowdown versus all these other data points that look like they're still fairly positive. And what I'm really kind of getting at ?is it feels like this could be a very short-term blip and that the recovery could be very quickly quick. Is that fair? Are there certain parts of the market? I don't know if it's ?you know private Tay patients versus you know um versus Medicare patients or anything else like that you can point to that says this is the one area that's really slowing down and that that we could see a snap back in that area um going forward.

Passages & reports (13)
  • it's been an absolute pleasure watching me grow this business. Um
  • I
  • guess I'm still a little hung up on this hippine um commentary about Q3 here, because if I
  • if
  • I look at your orthotech number, that was really good. It still seems like generally speak…
  • Um,
  • I actually talked to CDMO yesterday, they said things are pretty steady.
  • So
  • I'm trying to reconcile this slowdown versus all these other data points that look like th…
  • is it
  • feels like this could be a very short-term blip and that the recovery could be very quickl…
  • you know
  • private Tay patients versus you know um versus Medicare patients or anything else like tha…

Speaker 1

Look I I'm not gonna be I don't have a crystal ball so it's really going to be difficult to predict if there'll be a snap back. There have been confounding uh data points all year on the market. ?I mean one of the big hospital chains just announced their results earlier this week and talked about a significant slowdown in hips and knees. And they're a very large operator.

So that's a data point. Then there's other data points that say it's not as bad. So uh I think your point is is uh
is is ?the most accurate point is you know, things come back and it's hard to predict when they come ?back. You might be right, there could be a snapback, but I we're not gonna count on that as we give our guide.

We're assuming it stays where it is right now, the market stays where it is. We have seen times in the past where it's come back pretty quickly. We've seen other times where
it's taken ?a little longer. And I really don't have uh a great feel for uh for when this will return.

Passages & reports (11)
  • Look I I'm not gonna be I don't have a crystal ball so it's really going to be difficult t…
  • I
  • mean one of the big hospital chains just announced their results earlier this week and tal…
  • is is
  • the
  • most accurate point is you know, things come back and it's hard to predict when they come
  • back.
  • You might be right, there could be a snapback, but I we're not gonna count on that as we g…
  • it's taken
  • a
  • little longer. And I really don't have uh a great feel for uh for when this will return.

Speaker 7

Okay. ?And then just quickly on the vascular business. It did look like it popped back up here a little bit, which is great to see. Can you just talk about kind of the state of the vascular business and then and then your IVL plans as we go into 27? Thank

Passages & reports (3)
  • Okay.
  • And
  • then just quickly on the vascular business. It did look like it popped back up here a litt…

Speaker unclear

?you.

Passages & reports (1)
  • you.

Speaker 1

Yeah, look, the the state of the business is we have a very very uh stable and high performing sales organization, which was last year's challenge. If you recall, we had a lot of Salesforce challenges. That's well behind us and sales and marketing organizations really solid. Uh as we came back up after the cyber incident, we had a lot of challenges with our manufacturing facility.

And um, and that put us in a back order, and that was has been very, very painful. It it got better in the last quarter. Uh, we also had the one-time benefit, which I mentioned in my uh opening remarks, but I'm
starting to feel like ADS, the excitement from our customers is incredible. Customers are really excited about technology, the method of action, ?and it's the same customer that also uses our other peripheral vascular products.

So we believe that synergy is going to be fantastic. Not only will the product and we believe perform very well, but we believe it'll have a synergistic effect
?on the base business. So we're looking, we're just waiting for the FDA approval ?and the teams are already preparing for launch.

Passages & reports (9)
  • Yeah, look, the the state of the business is we have a very very uh stable and high perfor…
  • cyber incident, we had a lot of challenges with our manufacturing facility. And um, and th…
  • starting to feel like ADS, the excitement from our customers is incredible. Customers are …
  • and
  • it's the same customer that also uses our other peripheral vascular products. So we believ…
  • on
  • the base business. So we're looking, we're just waiting for the FDA approval
  • and
  • the teams are already preparing for launch.

Speaker 0

Your next question will come from the line of Matthew Taylor with Jeffries. Your line is unmuted.

Passages & reports (1)
  • Your next question will come from the line of Matthew Taylor with Jeffries. Your line is u…

Speaker unclear

?Hi,

Passages & reports (1)
  • Hi,

Speaker 7

thanks for taking the question. Um, I wanted to ask you a somewhat conceptual but also pragmatic question about AI. You know, you've seen in other areas of the market and even in healthcare recently, a lot of uh subsectors get credit for AI and the improvements that it could bring. It doesn't seem like that's really happened at all in in medtech, and yet ?you know you have a couple of businesses now with robotics and surgery and connected care that I would think over time could have significant product benefits, development benefits from AI.

So I was hoping you
?could talk about that a little bit, why you think MedTech hasn't gotten credit and the kind of benefits that we could see ?from AI on your business and in MedTech over

Passages & reports (8)
  • thanks for taking the question. Um, I wanted to ask you a somewhat conceptual but also pra…
  • that's really happened at all in in medtech, and yet
  • you know
  • you have a couple of businesses now with robotics and surgery and connected care that I wo…
  • could
  • talk about that a little bit, why you think MedTech hasn't gotten credit and the kind of b…
  • from
  • AI on your business and in MedTech over

Speaker unclear

?time. Yeah,

Passages & reports (1)
  • time. Yeah,

Speaker 1

I think what we've generally seen within within healthcare and med tech specifically is when you have new cycles of technology innovation, it tends to take longer before it has an impact. Just the regulated nature of our industry uh tends to cause take it a little bit longer. St. Robotics is a good example where robotics has taken hold in a lot of other industries and more recently has really started to take off in medtech.

We focused a lot of our energy on AI for uh innovation. Yes, we have some productivity initiatives ongoing, but we uh we have three FDA approved AI products, and you referenced a
couple of them uh when you were speaking in your question. And we have ?a number of other ones. Most of our product innovations that we're launching, anything in the enabling tech world, is likely going to have some kind of AI component to it.

And we're very excited about the promise of bringing science to healthcare and using AI to help um to help drive that science. So that
when you visit a surgeon, you're not just getting their one lived person's experience. You're going to be getting the wealth of data at the disposition to be able to make informed decisions, just like we do with our blueprint pre planning software for upper extremities.

So
?we are investing in it. You're going to hear more from us. It is always a little bit slower in MedTech. That's just the nature of innovations in a regulated industry.

Passages & reports (8)
  • I think what we've generally seen within within healthcare and med tech specifically is wh…
  • where robotics has taken hold in a lot of other industries and more recently has really st…
  • couple of them uh when you were speaking in your question. And we have
  • a
  • number of other ones. Most of our product innovations that we're launching, anything in th…
  • when you visit a surgeon, you're not just getting their one lived person's experience. You…
  • we
  • are investing in it. You're going to hear more from us. It is always a little bit slower i…

Speaker 7

Great. Thank you, Kevin.

Passages & reports (1)
  • Great. Thank you, Kevin.

Speaker 1

Thank you.

Passages & reports (1)
  • Thank you.

Speaker unclear

?Our

Passages & reports (1)
  • Our

Speaker 0

next question will come from Vijay Kamar with Evercore ISI. Your line is unmuted.

Passages & reports (1)
  • next question will come from Vijay Kamar with Evercore ISI. Your line is unmuted.

Speaker 7

Thank you for taking my question. Kevin, maybe my first one for you. When you look at uh 27 and the new products, did you listed ?out I think in the past when we've had these uh system nines and uh 1788 launches,

Passages & reports (3)
  • Thank you for taking my question. Kevin, maybe my first one for you. When you look at uh 2…
  • out
  • I think in the past when we've had these uh system nines and uh 1788 launches,

Speaker unclear

?you called them as

Passages & reports (1)
  • you called them as

Speaker 6

um

Passages & reports (1)
  • um

Speaker 7

supercycles. Um I'm curious on given the current environment, how would you characterize this ?uh impact of uh new new products? Is this still something um something that you would characterize as uh a super cycle for uh 27?

Passages & reports (3)
  • supercycles. Um I'm curious on given the current environment, how would you characterize t…
  • uh
  • impact of uh new new products? Is this still something um something that you would charact…

Speaker 1

Yeah, look, I'll

Passages & reports (1)
  • Yeah, look, I'll

Speaker unclear

?I

Passages & reports (1)
  • I

Speaker 3

the

Passages & reports (1)
  • the

Speaker 1

phrase was important because we had a number of platforms all being launched at the same ?time. And what I'd say is our innovation never stops. And sometimes the timing is just all at the same time. Sometimes it's metered out over, ?you know, you have a Power Tool launch one year, a camera launch the next year, ?a Mako upgrade the next year. So sometimes they're a little bit more spaced up.

They just happen to be condensed all in one uh sort of cluster, if you will. But I would say that we have great innovation ongoing. Innovation gets rewarded in MedTech. And so we are going to continue to invest in
innovation. And the platforms, I can tell you, 1888, I'm incredibly excited ?about. It has some features that uh it's going to be a step change.

So as 16.8 was a step change, 178 was was a little bit more incremental. I think 1888 is going to be fantastic.
?And then we have System 10 and we have all the other products across our portfolio that will be launching. Uh Neptune is always a great product that platform changes obviously drives growth. So every time we do these innovations, it drives growth.

And that is not changing. That dynamic isn't changing.
?And the capital market's really good. We're seeing our order book being elevated and we're not draining our backlog. And we're just uh frankly, if you think about medical as a good example, Lightback 35 and Procuity are still new products. I know they don't sound new, ?but these products ramp over an extended period of time just because the replacement cycle is a lot longer on bed stretchers and defibrillators.

And so the demand for those products are very significant. And and uh we're actually
?you know building extra capacity, especially in beds, uh the demand is very strong. And so those are still kind of new products, even though they've been launched a little while ago because of the replacement cycle. So we feel good about our innovation. It's it's alive and well in our company, and uh a number of those launches will occur in 27.

Passages & reports (19)
  • phrase was important because we had a number of platforms all being launched at the same
  • time.
  • And what I'd say is our innovation never stops. And sometimes the timing is just all at th…
  • you
  • know, you have a Power Tool launch one year, a camera launch the next year,
  • a
  • Mako upgrade the next year. So sometimes they're a little bit more spaced up. They just ha…
  • innovation. And the platforms, I can tell you, 1888, I'm incredibly excited
  • about.
  • It has some features that uh it's going to be a step change. So as 16.8 was a step change,…
  • And
  • then we have System 10 and we have all the other products across our portfolio that will b…
  • And
  • the capital market's really good. We're seeing our order book being elevated and we're not…
  • but
  • these products ramp over an extended period of time just because the replacement cycle is …
  • you know
  • building extra capacity, especially in beds, uh the demand is very strong. And so those ar…
  • those launches will occur in 27.

Speaker 4

That's helpful.

Passages & reports (1)
  • That's helpful.

Speaker unclear

?Maybe Christian one for you. I saw the um buyback in

Passages & reports (1)
  • Maybe Christian one for you. I saw the um buyback in

Speaker 7

the quarter. ?You have a new authorization ?for $3 billion. What what's the um I guess, uh philosophy behind capital allocation decisions, right? Is this something that you would consider as more opportunistic in uh nature when you think about uh deploying capital towards buybacks?

Passages & reports (5)
  • the quarter.
  • You
  • have a new authorization
  • for $3 billion.
  • What what's the um I guess, uh philosophy behind capital allocation decisions, right? Is t…

Speaker unclear

?Yeah,

Passages & reports (1)
  • Yeah,

Speaker 3

BJ, thanks for thanks for the question. As we said last quarter, you know, given the timing of when we have our deal flow uh from an MA standpoint, that we would look at more opportunistic share buyback um opportunities. And that's kind of what we saw. That's what we saw in the third quarter. Then we'll continue to evaluate that in the fourth quarter as well.

But just, you know, just to reiterate, and Nick talked a little bit about this in his prepared remarks,
?the capital allocation from our standpoint, the number one priority remains MA. And so we want to continue to put our dollars towards MA, which is given the timing of what we've had this year and what we see, this does just give us the opportunity to go out and do some opportunistic uh repurchases of share. ?

The
one thing I would say too is it doesn't take away from any of our firepower. I think what we've been able to demonstrate over the last several years is a continued increase in our ability to generate cash at a higher rate. Just some of its scales, some of it's the work that we're doing on working capital and other areas. And so that gives us a lot of flexibility now ?to go out and enhance our capital, our our capital allocation in terms of how we're thinking about ?where we put our dollars to dry shareholder value.

So this just gives us another lever to do

Passages & reports (12)
  • BJ, thanks for thanks for the question. As we said last quarter, you know, given the timin…
  • Then we'll continue to evaluate that in the fourth quarter as well. But just, you know, ju…
  • the
  • capital allocation from our standpoint, the number one priority remains MA. And so we want…
  • share.
  • The
  • one thing I would say too is it doesn't take away from any of our firepower. I think what …
  • doing on working capital and other areas. And so that gives us a lot of flexibility now
  • to
  • go out and enhance our capital, our our capital allocation in terms of how we're thinking …
  • where
  • we put our dollars to dry shareholder value. So this just gives us another lever to do

Speaker unclear

?that. Yeah

Passages & reports (1)
  • that. Yeah

Speaker 1

I'd just like to add something about MA. So we continue to remain a disciplined acquirer and we had a number of targets that we weren't able to close on this year. year. And some of those targets uh basically didn't trade at all, and we hope will actually come back to us uh as opportunities in the future. And so we do have an active pipeline, but with the sheer amount of cash we're generating, we're able to do these buybacks and still pursue all of the deals that uh that we're pursuing right ?now.

And we intend to remain active in MA going

Passages & reports (4)
  • I'd just like to add something about MA. So we continue to remain a disciplined acquirer a…
  • opportunities in the future. And so we do have an active pipeline, but with the sheer amou…
  • now.
  • And we intend to remain active in MA going

Speaker unclear

?forward.

Passages & reports (1)
  • forward.

Speaker unclear

?Our

Passages & reports (1)
  • Our

Speaker 0

next question will come from the line of Chris Pascal with Barclays. Your line is unmuted. Please go

Passages & reports (1)
  • next question will come from the line of Chris Pascal with Barclays. Your line is unmuted.…

Speaker unclear

?ahead. Thanks.

Passages & reports (1)
  • ahead. Thanks.

Speaker 6

You mentioned mitigating

Passages & reports (1)
  • You mentioned mitigating

Speaker unclear

?execution risk related to capital equipment sales as one of

Passages & reports (1)
  • execution risk related to capital equipment sales as one of

Speaker 4

the factors behind the

Passages & reports (1)
  • the factors behind the

Speaker unclear

?guidance revision. We were just hoping you can elaborate on that. Are you saying you're just being more conservative about what's assumed between now and year end

Passages & reports (1)
  • guidance revision. We were just hoping you can elaborate on that. Are you saying you're ju…

Speaker 7

just

Passages & reports (1)
  • just

Speaker unclear

?to absorb any delays that might crop

Passages & reports (1)
  • to absorb any delays that might crop

Speaker 7

up, or

Passages & reports (1)
  • up, or

Speaker unclear

?is there more to it in terms of what you're seeing out there in the market?

Passages & reports (1)
  • is there more to it in terms of what you're seeing out there in the market?

Speaker 3

No, Chris, I think I think that's right. When you when you listen to what Nick said earlier with regards to capital demand, demand is there. We're seeing very, very strong demand. talked about ramping production, which we've been doing and we were able to do on many of our lines, particularly around medical. It's just making sure that we can match that that production and supply with the demand as it continues to grow.

So again, it's it's a bit of a just a conservative, more conservative view in terms of our ability to just make sure that we are executing at the highest level
?to make sure that we can meet all the demand that is out there from a capital standpoint.

Passages & reports (4)
  • No, Chris, I think I think that's right. When you when you listen to what Nick said earlie…
  • just making sure that we can match that that production and supply with the demand as it c…
  • to
  • make sure that we can meet all the demand that is out there from a capital standpoint.

Speaker unclear

?Okay.

Passages & reports (1)
  • Okay.

Speaker 4

And then

Passages & reports (1)
  • And then

Speaker unclear

?you had called out weakness and hips previously. The knee performance this quarter was sort

Passages & reports (1)
  • you had called out weakness and hips previously. The knee performance this quarter was sor…

Speaker 5

of the incremental. Did some new dynamics emerge on the knee ?side in

Passages & reports (3)
  • of the incremental. Did some new dynamics emerge on the knee
  • side
  • in

Speaker unclear

?terms of your competitiveness in that

Passages & reports (1)
  • terms of your competitiveness in that

Speaker 5

segment? ?And if we think about the impactor as being a catalyst for improved relative performance in hips, is there something similar you're looking for to provide a boost in knees?

Passages & reports (3)
  • segment?
  • And
  • if we think about the impactor as being a catalyst for improved relative performance in hi…

Speaker 2

I mean, as we look at the market, we typically not tend to over-index on one specific quarter. If you look at the trends over the past, you know, 12 months, we really haven't seen any notable movement in share. We've been growing more in line with market. You know, if you look back over the past few years, we've certainly been exceeding market growth by a meaningful amount.

And over the past couple of quarters, for a variety of reasons that Kevin talked about, we've been growing more in line with the market.
?You know, as we think about our performance moving forward, we're excited to play offense and certainly having the hip impactor in our portfolio is going to allow us to do that in 2027 and beyond.

Passages & reports (4)
  • I mean, as we look at the market, we typically not tend to over-index on one specific quar…
  • the past few years, we've certainly been exceeding market growth by a meaningful amount. A…
  • You
  • know, as we think about our performance moving forward, we're excited to play offense and …

Speaker 3

The thing I would add from a knee standpoint, Kevin mentioned this, it's really just continued execution of our enabling tech strategy. So really talking about Mako 4, Mako RPS, along with the new products that he mentioned with Traffat Law Gold and MSI. I mean, those are those are elements that we feel give us a lot of opportunity to play offense, as Nick mentioned.

Passages & reports (2)
  • The thing I would add from a knee standpoint, Kevin mentioned this, it's really just conti…
  • us a lot of opportunity to play offense, as Nick mentioned.

Speaker 1

Yeah, and I'd add that the medial stabilized insert is actually doing very ?well and getting really positive feedback. It's a poly insert, but it's uh there's a demand in the market, and to be able to convert business. That's something we're very bullish about. That start has been very good. And I think that could be an accelerator going

Passages & reports (3)
  • Yeah, and I'd add that the medial stabilized insert is actually doing very
  • well
  • and getting really positive feedback. It's a poly insert, but it's uh there's a demand in …

Speaker unclear

?forward.

Passages & reports (1)
  • forward.

Speaker unclear

?Our

Passages & reports (1)
  • Our

Speaker 0

next question will come from Patrick Wood with UBS. You're unmuted, please go ahead.

Passages & reports (1)
  • next question will come from Patrick Wood with UBS. You're unmuted, please go ahead.

Speaker 5

Beautiful. Thanks,

Passages & reports (1)
  • Beautiful. Thanks,

Speaker unclear

?guys. Uh two quick ones. Uh one, just the State of the

Passages & reports (1)
  • guys. Uh two quick ones. Uh one, just the State of the

Speaker 7

Union on um on the smart care business like

Passages & reports (1)
  • Union on um on the smart care business like

Speaker unclear

?the Sarah and Care

Passages & reports (1)
  • the Sarah and Care

Speaker 5

AI. I ?know obviously asked last quarter, but that's that's been a big push this year. So that's the first one. ?And then the second, um, ?you know, extremity is obviously still doing very well. ?You know, what do you think it is that's distinct about say shoulder that is enabling it to sort of bat off some of the pressures then hip and knee has seen.

I know the base market growth is way higher, but in your mind, what's distinct

Passages & reports (9)
  • AI. I
  • know
  • obviously asked last quarter, but that's that's been a big push this year. So that's the f…
  • And
  • then the second, um,
  • you know,
  • extremity is obviously still doing very well.
  • You
  • know, what do you think it is that's distinct about say shoulder that is enabling it to so…

Speaker 7

about the patient pool that's enabling that to remain uh as strong as it sounds like it is?

Passages & reports (1)
  • about the patient pool that's enabling that to remain uh as strong as it sounds like it is…

Speaker unclear

?Thanks. Yeah,

Passages & reports (1)
  • Thanks. Yeah,

Speaker 2

so the first

Passages & reports (1)
  • so the first

Speaker 1

thing I'd say is smart care

Passages & reports (1)
  • thing I'd say is smart care

Speaker 2

had its uh best quarter

Passages & reports (1)
  • had its uh best quarter

Speaker 1

in our history, this past quarter. So what uh it was one a big contributor to the growth in medical. It's small relative to the size of medical in dollars, but it had very high double-digit growth ?in the quarter. Orders are picking up. The the integration ?of care AI with VoCERA is smooth. We've moved things to the cloud. So a lot of the early integration pains that we've had, we were through ?that.

And uh we are very excited about the momentum. The most excited I've been since, frankly, we've done those acquisitions. The integration is smooth, the customer experience is terrific. Virtual nursing is really becoming
?a common topic across hospitals to drive productivity, and care AI is very well suited for that. So I would say uh I'm I'm more bullish than ever about this. It's taken us a while, admittedly, but uh we had a terrific quarter in Q3, and that'll we expect that to continue going forward.

The second
part shoulder. Oh, shoulder. ?Yeah, shoulder. Look, it's a little bit uh a newer joint. If you think about hips and these have been around a long time, shoulder, the results from shoulder joint replacement are really terrific. In the past, there they sort of had didn't have the same uh degree of great outcomes. And obviously, we're the number one player in that with the tourney implants that we have, and so many innovations that we've launched short stem, stemless.

We now have Mako shoulder uh that application. That's creating uh a buzz. We uh so we have the polycarp uh uh polycarbon that's that's really uh great for sort of a hemi
arthroplasty. So we have so much innovation, and we've sort of been scaling those innovations in shoulder ID, which is a personalized glenoid. These are all launches we've had over the past two, three years that have kind of scaled and created uh tremendous differentiation ?in our shoulder business.

So the market as a whole is growing faster and has been growing faster than hip and knees for a while because it's a newer market where people are now seeing great outcomes, telling their friends about
?it. And then I think it's going to be a very uh big market in the future because a lot of people are living with pain and that they could get addressed. ?

And
I think that Mako shoulder uh will actually potentially grow the market as uh hip and knee surgeons that used to do shoulders, if they're familiar with Mako, they may very well uh go back to doing shoulders again, which they potentially had abandoned uh in the in the past.

Passages & reports (20)
  • in our history, this past quarter. So what uh it was one a big contributor to the growth i…
  • in
  • the quarter. Orders are picking up. The the integration
  • of
  • care AI with VoCERA is smooth. We've moved things to the cloud. So a lot of the early inte…
  • that.
  • And uh we are very excited about the momentum. The most excited I've been since, frankly, …
  • a
  • common topic across hospitals to drive productivity, and care AI is very well suited for t…
  • part shoulder. Oh, shoulder.
  • Yeah,
  • shoulder. Look, it's a little bit uh a newer joint. If you think about hips and these have…
  • one player in that with the tourney implants that we have, and so many innovations that we…
  • arthroplasty. So we have so much innovation, and we've sort of been scaling those innovati…
  • in
  • our shoulder business. So the market as a whole is growing faster and has been growing fas…
  • it.
  • And then I think it's going to be a very uh big market in the future because a lot of peop…
  • And
  • I think that Mako shoulder uh will actually potentially grow the market as uh hip and knee…

Speaker unclear

?Very clear. Thanks, guys.

Passages & reports (1)
  • Very clear. Thanks, guys.

Speaker 0

Our next question will come from Mike Matson with Needham and Company.

Passages & reports (1)
  • Our next question will come from Mike Matson with Needham and Company.

Speaker unclear

?Yeah,

Passages & reports (1)
  • Yeah,

Speaker 7

thanks for

Passages & reports (1)
  • thanks for

Speaker 4

taking my question. Um, just wanted to ask one on the commentary around the hip and E market.

Passages & reports (1)
  • taking my question. Um, just wanted to ask one on the commentary around the hip and E mark…

Speaker unclear

?I think you're

Passages & reports (1)
  • I think you're

Speaker 5

seeing two ?and a half percent growth. Was that uh kind of your estimate of the year-to-date growth or the growth in the third quarter? ?Uh, because just looking at your numbers in the third quarter, it

Passages & reports (5)
  • seeing two
  • and
  • a half percent growth. Was that uh kind of your estimate of the year-to-date growth or the…
  • Uh,
  • because just looking at your numbers in the third quarter, it

Speaker unclear

?looks like you were about flat, which would imply a

Passages & reports (1)
  • looks like you were about flat, which would imply a

Speaker 7

fair bit of

Passages & reports (1)
  • fair bit of

Speaker unclear

?market share loss.

Passages & reports (1)
  • market share loss.

Speaker 5

It sounds like you're sort of saying that you think you grew in line with the market. I'm just trying to figure out you know, is the market gone from ?you know low single digits to more flattish in the third quarter

Passages & reports (3)
  • It sounds like you're sort of saying that you think you grew in line with the market. I'm …
  • you know
  • low single digits to more flattish in the third quarter

Speaker unclear

?here? No, so

Passages & reports (1)
  • here? No, so

Speaker 3

so again, I think Nick mentioned this as well. You know, we we never look at a one-quarter in in this hip in the market and kind of say that's indicative of a trend. And so ?when we talk about two and a half, we're really trying to understand and extrapolate over the course of the year or even the last kind of the last trailing, 12 months.

Hard hard to do since not everybody's reported yet. And so we have to wait and see what that looks like. But that's our
our read on the market kind of year to date. Is that rough we'll call it roughly two and a half, is what we're what we're assuming is growing.

Passages & reports (4)
  • so again, I think Nick mentioned this as well. You know, we we never look at a one-quarter…
  • when
  • we talk about two and a half, we're really trying to understand and extrapolate over the c…
  • our read on the market kind of year to date. Is that rough we'll call it roughly two and a…

Speaker 7

Okay. But the message is ?that you think it was slower in the third quarter than the first half of

Passages & reports (3)
  • Okay. But the message is
  • that
  • you think it was slower in the third quarter than the first half of

Speaker unclear

?the year.

Passages & reports (1)
  • the year.

Speaker 3

We do think it's slowed down a bit more.

Passages & reports (1)
  • We do think it's slowed down a bit more.

Speaker unclear

?No,

Passages & reports (1)
  • No,

Speaker 3

we do think it slowed down a bit more in

Passages & reports (1)
  • we do think it slowed down a bit more in

Speaker unclear

?the

Passages & reports (1)
  • the

Speaker 0

next question will come from Jason Bedford with Raymond James.

Passages & reports (1)
  • next question will come from Jason Bedford with Raymond James.

Speaker unclear

?Hi,

Passages & reports (1)
  • Hi,

Speaker 0

this is Elaine on for Jason. Thanks

Passages & reports (1)
  • this is Elaine on for Jason. Thanks

Speaker unclear

?for taking

Passages & reports (1)
  • for taking

Speaker 6

the question. You talked about the factors driving the oracle slowdown, and ?I was wondering, are you seeing similar dynamics have an impact on met surge volumes, or would you say that med surge is more insulated given the acute nature of the procedures?

Passages & reports (3)
  • the question. You talked about the factors driving the oracle slowdown, and
  • I
  • was wondering, are you seeing similar dynamics have an impact on met surge volumes, or wou…

Speaker 2

Yeah, the latter. We see this more insulated. We have not seen the slowdown there. Preston talked about our growth drivers heading into Q4, and a lot of those are on the MedSerge side.

Passages & reports (1)
  • Yeah, the latter. We see this more insulated. We have not seen the slowdown there. Preston…

Speaker 6

Okay, thanks. And I'll have a follow-up. So Orthotech came in a bit better than our expectation, despite the broader ortho softness. Can you talk about what enabled it to do better? And do you have an update on the progress with Mako Showder and Mako RPS? Thanks.

Passages & reports (1)
  • Okay, thanks. And I'll have a follow-up. So Orthotech came in a bit better than our expect…

Speaker 1

Yeah. So yeah, we were very pleased with the Orthotech performance. Mako growth was tremendous. And as a reminder, we have a balance between upgrades as well as brand new installations. And that balance continues since we launched ?the Mako 4 platform. We also had a very strong performance from our orthopedic instruments business. So those are the power tool type business. They did very well.

Capital sales there were very strong in the quarter. So uh those are both very good.
?And then Mako RPS uh is off to a slow start. Uh really good customer feedback, but we've got to get our sales force playing offense. ?And they were a bit distracted last quarter. So we're gonna we have incentives in place and a commercial offense that's gonna lean in a lot more on RPS as we go uh forward.

And then the shoulder for Mako is uh getting really, really good feedback and contributing to the shoulder growth.

Passages & reports (7)
  • Yeah. So yeah, we were very pleased with the Orthotech performance. Mako growth was tremen…
  • the
  • Mako 4 platform. We also had a very strong performance from our orthopedic instruments bus…
  • And
  • then Mako RPS uh is off to a slow start. Uh really good customer feedback, but we've got t…
  • And they
  • were a bit distracted last quarter. So we're gonna we have incentives in place and a comme…

Speaker unclear

?Our

Passages & reports (1)
  • Our

Speaker 0

next question will come from Mike Kratkey with Lyrink Partners. Your line is open. Please go ahead.

Passages & reports (1)
  • next question will come from Mike Kratkey with Lyrink Partners. Your line is open. Please …

Speaker unclear

?Yeah,

Passages & reports (1)
  • Yeah,

Speaker 7

hi.

Passages & reports (1)
  • hi.

Speaker unclear

?This is uh

Passages & reports (1)
  • This is uh

Speaker 5

Sam on for Mike. Thanks for taking our question. Um, so it just seems like we're hearing antidotes of price competition getting more intense in orthopedics. Um, so I was just wondering what you guys are seeing out there on the pricing side and your expectations for 2027.

Passages & reports (1)
  • Sam on for Mike. Thanks for taking our question. Um, so it just seems like we're hearing a…

Speaker unclear

?Yeah,

Passages & reports (1)
  • Yeah,

Speaker 3

so from a price perspective, you know, we've maintained kind of our same our same expectations through the year. I mean, we expect modest price across the entirety of our portfolio. That'll likely come from more on the med search side. We'll get some positive price. And on the

Passages & reports (1)
  • so from a price perspective, you know, we've maintained kind of our same our same expectat…

Speaker 1

ortho side,

Passages & reports (1)
  • ortho side,

Speaker unclear

?you

Passages & reports (1)
  • you

Speaker 3

know, we're

Passages & reports (1)
  • know, we're

Speaker 1

trying to hold as much

Passages & reports (1)
  • trying to hold as much

Speaker 3

price as possible, but we'll end up in a slightly negative position, which is ?not significantly different than where we were last year. And so from our perspective, we're we're not expecting anything, anything significantly different than that.

Passages & reports (3)
  • price as possible, but we'll end up in a slightly negative position, which is
  • not
  • significantly different than where we were last year. And so from our perspective, we're w…

Speaker 2

Yeah, you know, we I

Passages & reports (1)
  • Yeah, you know, we I

Speaker 1

picked up some noise in the market around price, prices going down because of bulk sales. So there is some activity of uh it's not happening at Stryker. We don't do bulk sales. We we report our price, we actually report price, which not everybody does in our market. And so um that's what I hear uh outside of that sort of base business, normal contracting, it's a pretty stable pricing environment.

Um so that that's the noise that we hear, but it certainly doesn't apply to

Passages & reports (2)
  • picked up some noise in the market around price, prices going down because of bulk sales. …
  • hear uh outside of that sort of base business, normal contracting, it's a pretty stable pr…

Speaker unclear

?us.

Passages & reports (1)
  • us.

Speaker 7

Got it,

Passages & reports (1)
  • Got it,

Speaker unclear

?helpful.

Passages & reports (1)
  • helpful.

Speaker 5

And then just on the vascular side, you know, can you provide any color on how much in share loss during this interim disruption ?um you kind of view as temporary versus potentially more durable um and you know how difficult it may be to get back any any block share in accounts um that have been disrupted.

Passages & reports (3)
  • And then just on the vascular side, you know, can you provide any color on how much in sha…
  • um
  • you kind of view as temporary versus potentially more durable um and you know how difficul…

Speaker unclear

?Yeah

Passages & reports (1)
  • Yeah

Speaker 3

so what I would say is is we feel really good about being able to get back on offense as Kevin mentioned. And so anything that that we feel like we've lost, we believe is is temporary and that we'll be able to get back out and start winning that business back. Certainly having ABS and and that launching that product sometime next year will be a big help as we continue to to to build out and diversify the portfolio uh to to have a winning offense in 207.

Passages & reports (2)
  • so what I would say is is we feel really good about being able to get back on offense as K…
  • and and that launching that product sometime next year will be a big help as we continue t…

Speaker unclear

?Our

Passages & reports (1)
  • Our

Speaker 0

next question will come from the line of Richard Newwitter with Truist. Your line is open, please go ahead.

Passages & reports (1)
  • next question will come from the line of Richard Newwitter with Truist. Your line is open,…

Speaker 7

Thanks

Passages & reports (1)
  • Thanks

Speaker unclear

?for taking the questions.

Passages & reports (1)
  • for taking the questions.

Speaker 5

Maybe just the

Passages & reports (1)
  • Maybe just the

Speaker unclear

?first

Passages & reports (1)
  • first

Speaker 4

uh

Passages & reports (1)
  • uh

Speaker 5

congrats on the CMR

Passages & reports (1)
  • congrats on the CMR

Speaker 4

surgical deal. I guess

Passages & reports (1)
  • surgical deal. I guess

Speaker 5

um

Passages & reports (1)
  • um

Speaker unclear

?you know

Passages & reports (1)
  • you know

Speaker 4

maybe you could just just tell us why that asset, you know Kevin, you've talked

Passages & reports (1)
  • maybe you could just just tell us why that asset, you know Kevin, you've talked

Speaker 5

a a lot in the past you don't feel rushed. Um you know you guys are kind of gonna make the right decision. And and just maybe also as you answer that, the the the why now, why that asset, and then um

Passages & reports (1)
  • a a lot in the past you don't feel rushed. Um you know you guys are kind of gonna make the…

Speaker 7

why not just purchase it outright?

Passages & reports (1)
  • why not just purchase it outright?

Speaker unclear

?Thank you.

Passages & reports (1)
  • Thank you.

Speaker 1

Yeah, I think I sort of mentioned this earlier in the call, but uh an outright purchase comes with a lot of risk and then huge costs for continued ongoing development. And we have to make sure that this is going to be a commercial success in the United States. That really will determine the ultimate success of CMR. And so we are going to actually run the sales offense in the United States.

And we know how to run sales. So we believe we're going to be very successful, but we don't want to put all our eggs in this basket. It's a high risk kind of a deal.

Passages & reports (2)
  • Yeah, I think I sort of mentioned this earlier in the call, but uh an outright purchase co…
  • ultimate success of CMR. And so we are going to actually run the sales offense in the Unit…

There's still ongoing development that's needed, and they have a really strong team. Their change to Versus Plus was been excellent. We've been talking to this company for a long time, for many years. We know them very, very well. We've watched their trajectory. They have a about 10 plus years of experience. And uh time over target in robotics is actually really important. We saw that with Mako.

Having all those years under their belt before we acquired
?it was massively helpful. But but we don't want ?to just jump in here. Unlike Mako, which ?had implants attached to it, this is a pure adjacency. And uh it's not something we wanted to rush into necessarily. And uh and it's just a risk we felt we didn't need or want to take at this time, and and also put a lot of other financial pressures onto the rest of our portfolio.

So it's financially de-risked, operationally de-risked. But we like the partner. We have a great relationship with their leadership. And uh that Perseus Plus, that the improvements that they made to that system, we always like the design, the modular nature,
?uh, easy to move around between rooms. So great for for the ASC or and great for ?if you have a lot of surgeons that want the robot.

Today, there's many surgeons that would love to use a robot, but they don't have one in their hospital. And uh, and this is, as I said, great for those high-volume procedures that'll switch from being laparoscopic and open uh into robotic. So the feedback
we did surgeon testing, ?uh, a lot of evaluations, and the feedback was really positive. Uh, we hired a medical director uh on uh as part of the endoscopy team, Dr.

Santiago Horgan, who is very famous, and um he looked at every single robot and was uh he was our chief advisor on this, but uh also used a
panel of surgeons to assess all different robotic technologies. There was a few that we liked, and this one uh was the clear winner. And um, but not jumping in ?uh all told is is because it's a new space, it's a pure adjacency. ?

Uh
there is obviously a large incumbent, and we have to be able to prove the US success. But uh our hope and our plan is uh that this does work and that we do eventually take it

Passages & reports (21)
  • There's still ongoing development that's needed, and they have a really strong team. Their…
  • time over target in robotics is actually really important. We saw that with Mako. Having a…
  • it
  • was massively helpful. But but we don't want
  • to
  • just jump in here. Unlike Mako, which
  • had
  • implants attached to it, this is a pure adjacency. And uh it's not something we wanted to …
  • So it's financially de-risked, operationally de-risked. But we like the partner. We have a…
  • uh,
  • easy to move around between rooms. So great for for the ASC or and great for
  • if
  • you have a lot of surgeons that want the robot. Today, there's many surgeons that would lo…
  • we did surgeon testing,
  • uh,
  • a lot of evaluations, and the feedback was really positive. Uh, we hired a medical directo…
  • panel of surgeons to assess all different robotic technologies. There was a few that we li…
  • uh
  • all told is is because it's a new space, it's a pure adjacency.
  • Uh
  • there is obviously a large incumbent, and we have to be able to prove the US success. But …

Speaker unclear

?out.

Passages & reports (1)
  • out.

Speaker 4

Thanks.

Passages & reports (1)
  • Thanks.

Speaker 5

And and maybe just ?one one on orthopedic robotics. You know, you have a competitor uh coming

Passages & reports (3)
  • And and maybe just
  • one
  • one on orthopedic robotics. You know, you have a competitor uh coming

Speaker unclear

?out with their

Passages & reports (1)
  • out with their

Speaker 4

monogram at some point next year.

Passages & reports (1)
  • monogram at some point next year.

Speaker 5

Just wanted to hear, ?Kevin, your thoughts on on you know how you know

Passages & reports (3)
  • Just wanted to hear,
  • Kevin,
  • your thoughts on on you know how you know

Speaker unclear

?how

Passages & reports (1)
  • how

Speaker 4

Mako's positioned or what you're expecting as as the features of that that that product eventually kind of hit the market and and any thoughts on on that. Thank

Passages & reports (1)
  • Mako's positioned or what you're expecting as as the features of that that that product ev…

Speaker unclear

?you. Yeah

Passages & reports (1)
  • you. Yeah

Speaker 1

well for now we're we're going to hold off making any comments until we see it in the marketplace. But we love our solution, which of course has multiple applications on the same robot, which this will not have And obviously proven success. Robots aren't easy. And as we've seen with other offerings in the marketplace, it takes a little while to get it to start to perform in a decent ?way.

And we still think we have the winning platform. We looked at this company obviously earlier on, but I'm going to reserve judgment and wait till we see what happens. Let's see it come to market. And all I can say is robots are
?hard. And it's not something that I'm really afraid of in the near term, but we'll

Passages & reports (6)
  • well for now we're we're going to hold off making any comments until we see it in the mark…
  • marketplace, it takes a little while to get it to start to perform in a decent
  • way.
  • And we still think we have the winning platform. We looked at this company obviously earli…
  • hard.
  • And it's not something that I'm really afraid of in the near term, but we'll

Speaker unclear

?see.

Passages & reports (1)
  • see.

Speaker unclear

?Our

Passages & reports (1)
  • Our

Speaker 0

next question comes from Matt Blackman with TD Cowan. Your line is now open.

Passages & reports (1)
  • next question comes from Matt Blackman with TD Cowan. Your line is now open.

Speaker 4

Hi, thanks for taking the questions. It's Drew on for Matt.

Passages & reports (1)
  • Hi, thanks for taking the questions. It's Drew on for Matt.

Speaker unclear

?Kevin, just uh one for

Passages & reports (1)
  • Kevin, just uh one for

Speaker 5

you and then one for uh for Preston. ?Uh but you were talking about CMR a few times in the call, but I'm just curious if you could give us maybe ?uh a deeper view on where do you think the ?biggest opportunity is? Is it just conversion from lap or open? Just which bucket do you think has the largest opportunity? And maybe how should we think about the potential for you to integrate your tower and camera business in with CMR?

You mentioned 188, uh 1888

Passages & reports (7)
  • you and then one for uh for Preston.
  • Uh
  • but you were talking about CMR a few times in the call, but I'm just curious if you could …
  • uh
  • a deeper view on where do you think the
  • biggest
  • opportunity is? Is it just conversion from lap or open? Just which bucket do you think has…

Speaker unclear

?is

Passages & reports (1)
  • is

Speaker 4

coming. It's a step

Passages & reports (1)
  • coming. It's a step

Speaker unclear

?change

Passages & reports (1)
  • change

Speaker 5

uh versus 1788. ?Uh, just curious if that really helps you go deeper in existing surgical categories, or does this even open up new surgical areas for

Passages & reports (3)
  • uh versus 1788.
  • Uh,
  • just curious if that really helps you go deeper in existing surgical categories, or does t…

Speaker unclear

?you?

Passages & reports (1)
  • you?

Speaker 1

Yeah, so uh the second part of your question I'm really not gonna answer because uh we we haven't bought the company. And in fact, we haven't even closed the our agreement, but it'll close uh shortly. Uh but really we're gonna work with uh CMR. It's still their company. We're an investor. Uh, we have a stake in the company and we have a board seat with the company.

But we'll work with them. You do need a tower with their robot. And uh obviously, if we're commercializing the robot, uh chances are we're gonna try
?to partner with our tower. But uh, there are a lot of synergy opportunities. And we will work with them on some of those synergy opportunities. And then ultimately, when we eventually acquire this, then we'll be able to talk a lot more openly about our plans.

So for now, it it is a relationship that
we have with ?them. And uh we will show them things that we can collaborate, but ultimately they're gonna have to agree because it is ?you know it is still their company. Definitely the biggest opportunity is conversion ?of laparoscopic and open to robotic. That's where the biggest opportunity is. Again, it doesn't mean that we won't be chosen in some cases versus uh the competitive offering, but that's really not the that's not the prime focus.

There are a lot of procedures done today, and laparoscopy isn't easy. Labroscopic suturing is not easy.
It's not an easy robot. Robotics will make these procedures easier to perform. And uh, and we think that'll drive much higher adoption ?of minimum invasive surgery.

Passages & reports (14)
  • Yeah, so uh the second part of your question I'm really not gonna answer because uh we we …
  • have a stake in the company and we have a board seat with the company. But we'll work with…
  • to
  • partner with our tower. But uh, there are a lot of synergy opportunities. And we will work…
  • we have with
  • them.
  • And uh we will show them things that we can collaborate, but ultimately they're gonna have…
  • you
  • know it is still their company. Definitely the biggest opportunity is conversion
  • of
  • laparoscopic and open to robotic. That's where the biggest opportunity is. Again, it doesn…
  • It's not an easy robot. Robotics will make these procedures easier to perform. And uh, and…
  • of
  • minimum invasive surgery.

Speaker unclear

?Thank you. And for Preston,

Passages & reports (1)
  • Thank you. And for Preston,

Speaker 5

uh earlier in the call, I think uh someone mentioned that there was a Chinese uh China JV uh revenue head in the quarter. Just wondering if you might be able to quantify that ?for the vascular business. Thanks for taking the questions.

Passages & reports (3)
  • uh earlier in the call, I think uh someone mentioned that there was a Chinese uh China JV …
  • for
  • the vascular business. Thanks for taking the questions.

Speaker 3

Yeah, so so yes, we did get a one-time benefit out of our joint venture in China. As a reminder, this was a joint venture that was in place when we purchased Anari. We aren't calling it out specifically. What I would just say is underlying business, the ongoing underlying peripheral vascular and vascular business is about in line with the comments that I made ?uh earlier in September and similar to the to the performance and impact that it had on the business uh in second quarter.

Passages & reports (4)
  • Yeah, so so yes, we did get a one-time benefit out of our joint venture in China. As a rem…
  • is about in line with the comments that I made
  • uh
  • earlier in September and similar to the to the performance and impact that it had on the b…

Speaker 0

Our final question will come from Vic Chopra with BMO Capital Markets. Your line is now unmuted.

Passages & reports (1)
  • Our final question will come from Vic Chopra with BMO Capital Markets. Your line is now un…

Speaker 7

Thanks for squeezing me in. Just ?a quick question for you on ZuraMed. I'm just wondering how that fiber locker technology expands the soft tissue augmentation portfolio and anything you can share around revenues and timelines.

Passages & reports (3)
  • Thanks for squeezing me in. Just
  • a quick
  • question for you on ZuraMed. I'm just wondering how that fiber locker technology expands t…

Speaker unclear

?Thank you.

Passages & reports (1)
  • Thank you.

Speaker unclear

?to

Passages & reports (1)
  • to

Speaker 1

attach to to drive that fixation. We love the applicator. The applicator is kind of almost like magic the way it applies the fixation. Really, really clever design. And we think it's going to be an absolute winner. As you know, this is an area that rotator cuffs have to have a lot of failures. And this additional sort of augmentation will provide tremendous clinical benefits.

And it has been a fast-growing part of the market. We did not have a solution for this. And we looked at some others and we passed on them because we didn't feel they were differentiating enough. And this one is uh the one
we feel will be uh an absolute winner. We already have, ?and the timing is just perfect because we've launched all of these shoulder products, and now we have this augment as well.

So it's uh it's really uh something that we're excited about. We'll share more details as we launch it
?in terms of Cassess, but I do believe it's going to be a winner in the

Passages & reports (7)
  • attach to to drive that fixation. We love the applicator. The applicator is kind of almost…
  • And this additional sort of augmentation will provide tremendous clinical benefits. And it…
  • we feel will be uh an absolute winner. We already have,
  • and
  • the timing is just perfect because we've launched all of these shoulder products, and now …
  • in
  • terms of Cassess, but I do believe it's going to be a winner in the

Speaker unclear

?market.

Passages & reports (1)
  • market.

Speaker 0

There are no further questions. I will turn the call over to Kevin Lobo for closing remarks.

Passages & reports (1)
  • There are no further questions. I will turn the call over to Kevin Lobo for closing remark…

Speaker unclear

?So

Passages & reports (1)
  • So

Speaker 1

thank you all for joining our call and thanks for all the time we've had over the years. We look forward to sharing our Q4 and full year 2026 result with you at the next earnings ?call. Thank

Passages & reports (3)
  • thank you all for joining our call and thanks for all the time we've had over the years. W…
  • call.
  • Thank

Speaker unclear

?you.

Passages & reports (1)
  • you.

Speaker unclear

?This

Passages & reports (1)
  • This

Speaker 0

concludes the third quarter, 2026, striker earnings call. You may now disconnect.

Passages & reports (1)
  • concludes the third quarter, 2026, striker earnings call. You may now disconnect.
Source, accuracy & exportsMay contain errorsAccuracy unmeasured. Speakers are anonymous voice labels, local to this call. No names are verified. Section starts and timestamps are inferred. Speakers are anonymous voice labels, local to this call. No names are verified. Section starts and timestamps are inferred.

Short unclear spans may appear inline between matching voice IDs. The ? marker retains unknown attribution; no voice identity is inferred for those words.

AI-generated transcript; names, numbers and wording may be inaccurate.

Speaker IDs are anonymous and local to this call. Section boundaries and timestamps are inferred.

The diarizer reached its eight-speaker limit; distinct voices may share an ID.

Zero-duration alignments: 0. Unassigned words: 495. No alignment has been repaired. Timestamps locate passages in the source recording; decimal positions do not establish word-level precision.

Official issuer source ↗ · Report an issue

Published transcript · Full recording available. Publication updated 2026-11-15T22:16:55.392Z.
Transcript version v1-999d30840ed20c7a7fca · publication revision 1. Generated by AI; no listener-verified accuracy score is available.

Dotted spans marked ? have an unclear speaker. They remain unattributed even when shown inside a surrounding turn.

Copy or download
ReadableGrouped by speaker and paragraph with timestamps. Stored words unchanged.
As storedOne line per stored segment with its original speaker ID and start time. Exactly the stored words.
Official issuer source ↗Company overview ↗
TRANSCRIPT FEEDBACK

Report a passage

Your report is queued privately for review. It does not change this transcript automatically. Please avoid personal information.